A federal appeals court is today due to again deliberate on whether it's possible to patent...


A federal appeals court is today due to again deliberate on whether it's possible to patent isolated human genes in a case that will probably have wide ramifications for the development of medical tests and treatments. The case involves Myriad Genetics (MYGN), which holds patents - at the moment - that allow it to genetically screen those at risk of breast or ovarian cancer.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs